Literature DB >> 79319

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.

.   

Abstract

A comparison was made between 4 regimens of chemotherapy given for 6 or 8 months, with a 6-month period of follow-up thus far. One regimen, which had a 2-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily administration of thiacetazone and isoniazid, was very effective. Shortening the initial intensive 4-drug phase to 1 month produced a less successful regimen unless the continuation phase was twice-weekly administration of streptomycin, isoniazid, and pyrazinamide. A regimen in which pyrazinamide was omitted from the initial intensive 2-month phase was also less effective. All patients were inpatients for 6 months to ensure that every dose of drug was fully supervised during this period. Increasing the total duration of chemotherapy from 6 months to 8 months was associated with a significant decrease in the early relapse rate in all 4 regimens, although the above differences between the regimen remained. The applicability of the findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 79319     DOI: 10.1164/arrd.1978.118.1.39

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States.

Authors:  M M Hannan; E P Desmond; G P Morlock; G H Mazurek; J T Crawford
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 2.  Cost effectiveness of antituberculosis interventions.

Authors:  A Castelo; P A Mathiasi; R Iunes; A L Kritski; M Dalcolmo; F Fiuza de Melo; M Drummond
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

3.  Short course chemotherapy for tuberculosis in children.

Authors:  B L Varudkar
Journal:  Indian J Pediatr       Date:  1985 Nov-Dec       Impact factor: 1.967

4.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 5.  Short-course therapy for tuberculosis.

Authors:  M Aquinas
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

6.  Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Authors:  Kwok-Chiu Chang; Chi-Chiu Leung; Wing-Wai Yew; Eric Chung-Ching Leung; Wai-Man Leung; Cheuk-Ming Tam; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 7.  Challenges in the clinical assessment of novel tuberculosis drugs.

Authors:  Kelly E Dooley; Patrick P J Phillips; Payam Nahid; Michael Hoelscher
Journal:  Adv Drug Deliv Rev       Date:  2016-01-28       Impact factor: 15.470

8.  Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.

Authors:  Mengqiu Gao; Jingtao Gao; Jian Du; Yuhong Liu; Yao Zhang; Liping Ma; Fengling Mi; Liang Li; Shenjie Tang
Journal:  BMC Infect Dis       Date:  2017-06-19       Impact factor: 3.090

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

Review 10.  Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman
Journal:  PLoS Med       Date:  2009-09-15       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.